Welcome to our dedicated page for SciSparc Ltd. SEC filings (Ticker: SPRC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on SciSparc Ltd.'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into SciSparc Ltd.'s regulatory disclosures and financial reporting.
SciSparc Ltd. reports that AutoMax Motors Ltd. has obtained a court-ordered pause in the approval process for their planned merger. On September 16, 2025, AutoMax filed a motion with the Jerusalem District Court under Israeli companies law, asking to stay proceedings related to its shareholders’ approval of the merger with SciSparc and a merger subsidiary.
The Court granted the request, staying the proceedings until September 30, 2025, or until AutoMax notifies the Court that conditions precedent to completing the merger have not been met, whichever comes first. AutoMax sought this stay because recent developments in its business operations raise uncertainty about its ability to satisfy the closing conditions for the merger.
SciSparc Ltd. reports that in August 2025 certain investors converted portions of previously issued convertible debentures into equity. The debentures were originally issued in an aggregate principal amount of $4.2 million and are convertible into ordinary shares. Based on conversion notices submitted by investors, the company issued 999,528 ordinary shares upon conversion of outstanding principal and accrued interest. After these issuances, SciSparc had 1,622,273 ordinary shares issued and outstanding as of August 28, 2025, and $175,000 principal amount of debentures remained outstanding.
SciSparc Ltd. reports that its shareholders have approved a merger with a leading parallel vehicle importer in Israel. The company also notes that shareholders of AutoMax, the target business, have approved merging AutoMax with SciSparc.
The report furnishes two press releases as exhibits describing these approvals and incorporates this information into multiple existing SciSparc registration statements on Forms F-3 and S-8, meaning the merger details become part of those offering documents going forward.
SciSparc Ltd. reports that its shareholders approved all proposals presented at an adjourned special general meeting held on August 26, 2025. The proposals were approved by the required majority under Israeli Companies Law and the company’s amended and restated articles of association, as described in the proxy statement/prospectus sent to shareholders.
The company also states that this report is incorporated by reference into several of its existing registration statements on Form F-3 and Form S-8, meaning those registration statements now include this update as part of their disclosed information.
SciSparc Ltd. convened a Special General Meeting of Shareholders on August 25, 2025, but the meeting was adjourned due to lack of quorum. The adjourned Special Meeting is scheduled for August 26, 2025 at 8:00 a.m. Eastern / 3:00 p.m. Israel time at the company’s Tel Aviv offices.
If a quorum is still not present within half an hour of the new start time, any shareholders present in person or by proxy, or who have delivered a proxy card, will constitute a quorum and may vote on the meeting matters. Proxy cards already delivered will be used at the adjourned meeting.
SciSparc Ltd. furnished a Form 6-K to update investors about a new development in its collaboration with Clearmind. The company reported that on August 7, 2025 it issued a press release titled “SciSparc-Clearmind Collaboration Leads to Publication of International Patent Application for Novel Combination Therapy Targeting Obesity and High Blood Sugar.” This indicates the partners are pursuing patent protection for a combination therapy aimed at metabolic conditions such as obesity and elevated blood sugar levels.
The Form 6-K also states that this update is incorporated by reference into SciSparc’s existing shelf registration statements on Form F-3 and its equity compensation registration statements on Form S-8, meaning the disclosure becomes part of those securities offering documents.